India’s pharmaceutical industry supplies around 40%, 25%, and 50% of the generic medicines prescribed in the United States, the United Kingdom, and Africa, respectively, yet a shifting global market toward biologics and vaccines highlights a critical structural mismatch. Despite generating billions in export revenue, the sector remains heavily anchored in high-volume, low-value small-molecule active pharmaceutical ingredients.
The Volume Paradox Shaping the Pharmacy of the World
Historical policy interventions, including the Indian Patents Act, 1970, which granted patents only for manufacturing processes, allowed domestic firms to reverse-engineer patented medicines through alternative production methods. This foundation transformed India into an indispensable global supplier of affordable generic drugs. In 2025, the country exported pharmaceuticals worth $22.6 billion to 200 countries, securing a consistent trade surplus.
A profound disconnect has emerged between this traditional export profile and rapid shifts in global demand. While the global pharmaceutical market (HS 30) doubled from $508.7 billion to $1.03 trillion between 2015 and 2025, India’s overall market share stagnated at around 2.5%. The core of global spending has pivoted away from conventional retail medicaments toward blood products, vaccines, and immunologicals.
| Pharmaceutical Segment | Global Import Share Shift (2015–2025) | India’s Global Market Share (2025) |
|---|---|---|
| Retail Medicaments & Formulated Drugs (HS 3004) | Declined from 68.8% to 55.6% | 4.0% |
| Blood Products, Vaccines & Immunologicals (HS 3002) | Rose from 24.1% to 38.0% | 0.6% |
| Hormones & Hormone Analogues (HS 2937) | Rose from 11.2% to 37.5% | 0.3% |
Missing the Biologics Boom in Global Trade
As advanced therapeutics dominate Western markets, major exporters have systematically reoriented their portfolios. Biopharmaceuticals (HS 3002) accounted for nearly 60% of pharmaceutical exports from the United States, and more than half of those from Switzerland and Ireland, in 2025. In contrast, these items comprised 9% of India’s pharmaceutical exports.
Switzerland’s leadership in biologics, immunologicals and vaccines (HS 3002) stems from a multi-decade innovation ecosystem supported by research and development expenditures exceeding 3.4% of GDP. Specialized life sciences clusters including Espace Mittelland-Bassin Lémanique and Zurich-Zug-Lucerne-Schaffhausen foster deep industry-academia collaboration.
India, by comparison, faces declining domestic research and development intensity. Structural bottlenecks continue to hinder local commercialization. Academic institutions prioritize publications and patents, while private manufacturers chase immediate commercial products. Consequently, promising research frequently stalls at the proof-of-concept stage rather than advancing to clinical trials and commercial manufacturing.
Navigating Regulatory and Market Access Barriers
Clinical trials account for nearly 70% of out-of-pocket research and development costs globally. Although India possesses a large patient pool and substantial scientific talent, regulatory uncertainty, lengthy approval timelines, fragmented ethics approvals, and weak coordination among research institutions, hospitals, academia, and industry constrain its potential as a clinical research destination.
Market access remains an additional hurdle. Developing economies such as China, Brazil, and Russia represent a $159.4 billion import market, yet India captures just 1.7% of it, pulling in $1.15 billion in exports. In China, the National Volume-Based Procurement program heavily favors domestic manufacturers with integrated active pharmaceutical ingredient supply chains. In Brazil, stringent requirements enforced by the National Health Surveillance Agency create prolonged approval timelines and high compliance costs.
Policy interventions highlighted in NITI Aayog (2026) emphasize that moving beyond a volume-led generic model requires addressing these regulatory friction points. Transitioning toward complex active pharmaceutical ingredients and advanced biologics will determine whether the country can bridge the gap between its historic manufacturing strengths and the future of global medicine.
- Poland Constitutional Tribunal Crisis: Police Intervention and Protests Erupt in Warsaw
- Joe Miñoso to Exit Chicago Fire in 300th Episode
- Nubank: Latin America’s Largest Digital Bank Expands into the US Market (world-today-journal.com)
- India faces Japan in Asian Champions Trophy hockey (archyworldys.com)
